Table 9. ATTR stabilizers for the treatment of transthyretin amyloid cardiomyopathy.

	Tafamidis	Diflunisal	AG10
Evidence	FDA, EMA, and TFDA approved	Off-label use	Under investigation
Dose	61 mg (tafamidis meglumine) QD	250 mg BID	N/A
Side effect	No	Fluid retention	N/A
		Renal dysfunction
		GI bleeding

ATTR, transthyretin; BID, twice per day; EMA, European Medicines Agency; FDA, Food and Drug Administration; GI, gastrointestinal; N/A, not applicable; QD, once per day; TFDA, Taiwan Food and Drug Administration.